Inovio Pharmaceuticals gets FDA approval for first product
What it means
- What to watch: Good trial results are only step one; approval timing and pricing decide how much it is worth.
- How the stock is trading: $INO +159.13% in the latest session.
- Timing: It landed after the closing bell, so the session change beside it was locked in before the story existed. The next session is the first that could react.
Where the stock stands
$INO last traded at $2.00, +159.13% on the session. That puts it 26% shy of its 52-week high of $2.72 and 257% clear of its low of $0.56 — a little above the middle of the range. Over the year it has ranged 386% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $INO page.
How much coverage it is getting
In the last 30 days Wook has filed 2 stories about $INO — 1 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal — something has the newsroom's attention. Across those stories 1 read bullish, 1 neutral and 0 bearish. This one reads bullish, so it sits squarely with the crowd. This is the only one from Investing.com; the rest came from other outlets. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$INO earnings in 10 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $INO page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $INO is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. It reads bullish at medium severity because of “approval” in the wording, with nothing on the bearish side to offset it. It was matched to $INO. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on October 30, 2026. $INO has moved -5.21% ($2.11 to $2.00). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.